Drug use evaluation of bivalirudin for injection based on weighted TOPSIS method

Published on Apr. 29, 2024Total Views: 1419 times Total Downloads: 419 times Download Mobile

Author: LI Ruijuan ^1, ² LI Meijuan ³ MI Xiaolong ^2, ⁴ CHEN Weihong ^1, ² LI Zhihong ^1, ² WANG Xiaomin ^1, ²  ZHANG Jinhua ⁵

Affiliation: 1. Department of Pharmacy, Shanxi Bethune Hospital / Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital / Third Hospital of Shanxi Medical University, Taiyuan 030032, China 2. Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China 3. Department of Pharmacy, First Hospital of Shanxi Medical University, Taiyuan 030001, China 4. Department of Cardiovascular Medicine, Shanxi Bethune Hospital / Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital / Third Hospital of Shanxi Medical University, Taiyuan 030032, China 5. Department of Pharmacy, Fujian Maternity and Child Health Care Hospital, Fuzhou 350001, China

Keywords: Bivalirudin Drug use evaluation Weighted TOPSIS method Rational drug use

DOI: 10.12173/j.issn.1005-0698.202306020

Reference: LI Ruijuan, LI Meijuan, MI Xiaolong, CHEN Weihong, LI Zhihong, WANG Xiaomin,ZHANG Jinhua.Drug use evaluation of bivalirudin for injection based on weighted TOPSIS method[J].Yaowu Liuxingbingxue Zazhi,2024, 33(4):361-370.DOI: 10.12173/j.issn.1005-0698.202306020.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To establish the drug use evaluation (DUE) standard of bivalirudin for injection, and to evaluate the use of the drug by weighted TOPSIS method, so as to provide a reference for rational use of bivalirudin.

Methods Based on the package insert, clinical guidelines and consensus of experts of bivalirudin, the DUE standards were developed, and the weighted TOPSIS method was used to evaluate the rationality of the discharge medical records of Shanxi Bethune Hospital from January 1st to June 30th in 2022.

Results Incorporating 108 medical records involving the use of bivalirudin for injection, 88 cases (81.48%) exhibited a high degree of adherence (C_i≥0.8) between the prescribed drug regimens and the optimal recommendations, which is considered reasonable. Additionally, 19 cases (17.59%) fell within the range of 0.6≤C_i<0.8, indicating a generally reasonable adherence. Only one case (0.93%) had a C_i<0.6, suggesting an unreasonable level of adherence. The irrational situations about various evaluation indicators in the DUE were mainly manifested in the inappropriate dosages of administration (12.04%), inappropriate disposal of adverse reactions (11.11%), using medicine with contraindications (3.70%), using medicine without indication (1.85%), inappropriate monitoring of adverse reactions (0.93%), etc.

Conclusion The established DUE standards for bivalirudin are intuitive and comprehensive, and the evaluation results show that there are some unreasonable situations in the use of bivalirudin in the hospital, and it is necessary to standardize the use of bivalirudin in terms of dosages, disposal of adverse reactions, indication and contraindication.

Full-text

Please download the PDF version to read the full text: download

References

1.周莹, 何志龙, 孔毅. 凝血酶抑制剂的研究进展[J].中国药业, 2013, 22(12): 9-12. [Zhou Y, He ZL, Kong Y. Research progress on thrombin inhibitor[J]. China Pharmaceuticals, 2013, 22(12): 9-12.] DOI: 10.3969/j.issn.1006-4931.2013.12.005.

2.Laine M, Lemesle G, Dabry T, et al. Bivalirudin during percutaneous coronary intervention in acute coronary syndromes[J]. Expert Opin Pharmacother, 2019, 20(3): 295-304. DOI: 10.1080/14656566.2018.1551361.

3.Ong C, Bangalore S. Does VALIDATE-SWEDEHEART invalidate the use of bivalirudin in myocardial infarction?[J]. J Thorac Dis, 2018, 10(1): 70-74. DOI: 10. 21037/jtd.2017.12.100.

4.Dymova L, Sevastjanov P, Tikhonenko A. A direct interval extension of TOPSIS method[J]. Expert Syst Appl, 2013, 40(12): 4841-4847. DOI: 10.1016/j.eswa.2013.02.022.

5.Park T, Muzumdar J, Kim H. Digital health interventions by clinical pharmacists: a systematic review[J]. Int J Environ Res Public Health, 2022, 19(1): 532. DOI: 10.3390/ijerph19010532.

6.叶陈丽, 张友恒, 宋芳, 等. 华法林药物利用评价标准的建立与应用[J]. 中国药师, 2020,23(8): 1572-1577. [Ye CL, Zhang YH, Song F, et al. Establislament and application of drug use evaluation criteria for warfarin[J]. China Pharmacist, 2020, 23(8): 1572-1577.] DOI: 10.3969/j.issn.1008-049X.2020.08.021.

7.林小娟, 黄小红, 黄涓涓, 等. 利伐沙班药物利用评价标准的建立与应用[J]. 中国现代应用药学, 2020, 37(20): 2543-2548. [Lin XJ, Huang XH, Huang JJ, et al. Establishment and application of drug use evaluation standard of rivaroxaban[J]. Chinese Journal of Modern Applied Pharmacy, 2020,37(20): 2543-2548.] DOI: 10.13748/j.cnki.issn1007-7693.2020.20.020.

8.王海平, 陈国权, 邱树胜, 等. 阿哌沙班药物利用评价标准建立和应用[J]. 药物流行病学杂志, 2022, 31(11): 749-755. [Wang HP, Chen GQ, Qiu SS, et al. Establishment and application of drug use evaluation criteria for apixaban[J]. Journal of Pharmacoepidemiology, 2022, 31(11): 749-755.] DOI: 10.19960/j.cnki.issn1005-0698.2022.11.006.

9.中国医师协会心血管内科医师分会血栓防治专业委员会, 《中华医学杂志》编辑委员会. 肝素诱导的血小板减少症中国专家共识(2017)[J]. 中华医学杂志, 2018, 98(6): 408-417. DOI: 10.3760/cma.j.issn.0376-2491. 2018.06.003.

10.Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2021, 42(23): 2298. DOI: 10.1093/eurheartj/ehab285.

11.Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2018, 39(2): 119-177. DOI: 10.1093/eurheartj/ehx393.

12.中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志, 2019, 47(10): 766-783. DOI: 10.3760/cma.j.issn.0253-3758.2019.10.003.

13.中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 非ST段抬高型急性冠状动脉综合征基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2021, 20(1): 6-13. DOI: 10.3760/cma.j.cn114798-20201030-01113.

14.McPherson S, Reese C, Wendler MC. Methodology update: Delphi studies[J]. Nurs Res, 2018, 67(5): 404-410. DOI: 10.1097/NNR.0000000000000297.

15.蒋莹莹, 詹尧平, 徐翔翔. LIKERT五分量表法在建立儿科人血白蛋白临床应用评价标准的应用[J].儿科药学杂志, 2023, 29(1): 1-4. [Jiang YY, Zhan YP, Xu XX. Establishment and application of clinical evaluation criteria for pediatric human serum albumin based on Likert five subscale method[J]. Journal of Pediatric Pharmacy, 2023, 29(1): 1-4. DOI: 10.13407/j.cnki.jpp.1672-108X.2023.01.001.

16.Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.

17.赵小丽, 朱倩倩, 赵佩, 等. 基于加权TOPSIS法评价重组人血小板生成素的合理使用[J]. 中国医院药学杂志, 2022, 42(4): 431-434. [Zhao XL, Zhu QQ, Zhao P，et al. Evaluation of recombinant human thrombopoietin utilization based on weighted TOPSIS method[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(4): 431-434.] DOI: 10.13286/j.1001-5213.2022.04.16.

18.吴孝安, 李小东, 孙伟, 等. 加权TOPSIS法评价肝胆及胰腺手术预防性使用抗菌药物的合理性[J]. 中国医院药学杂志, 2023, 43(4): 436-440. [Wu XA, Li XD, Sun W, et al. Evaluation of the rationality of prophylacticuse of antimicrobial drugs in hepatobiliary and pancreatic surgery by the weighed TOPSIS method[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(4): 431-434.] DOI: 10.13286/j.1001-5213.2023.04.16.

19.Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial[J]. JAMA, 2003, 289(7): 853-863. DOI: 10.1001/jama.289.7.853.

20.Medscape. Interactions for bivalirudin[EB/OL]. (2022-06-30) [2022-12-16]. http://www.medscape.com/.

21.Gargiulo G, Carrara G, Frigoli E, et al. Post-procedural bivalirudin infusion at full or low regimen in patients with acute coronary syndrome[J]. J Am Coll Cardiol, 2019 , 73(7): 758-774. DOI: 10.1016/j.jacc.2018.12.023.

22.中国医师协会心血管内科医师分会, 中国医师协会心血管内科医师分会血栓防治专业委员会, 中华医学会消化内镜学分会, 等. 急性冠状动脉综合征抗栓治疗合并出血防治多学科专家共识[J]. 中华内科杂志, 2016, 55(10): 813-824. DOI: 10.3760/cma.j.issn. 0578-1426.2016.10.021.

23.Franczyk-Skora B, Gluba A, Banach M, et al. Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease[J]. Arch Med Sci, 2013, 9(6): 1019-1027. DOI: 10.5114/aoms.2013.39792.

24.Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction[J]. Pharmacotherapy, 26(4): 452-460. DOI: 10.1592/phco.26.4.452.

25.何冬黎, 李倩, 吕漫, 等. 达比加群酯药物利用评价标准的建立与回顾性分析[J]. 中国医院药学杂志, 2022, 42(11): 1142-1146. [He DL, Li Q, Lyu M. Establishment and retrospective analysis of the evaluation criteria for drug utilization of dabigatran[J]. Chinese Journal of Hospital Pharmac, 2022, 42(11): 1142-1146.] DOI: 10.13286/j.1001-5213.2022.11.11.